PRQR
$1.78+0.02 (+1.42%)
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders wi...
Recent News
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) delivered earnings and revenue surprises of -12.50% and -36.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
ProQR: Q4 Earnings Snapshot
LEIDEN, Netherlands (AP) — ProQR Therapeutics NV (PRQR) on Thursday reported a loss of $9.1 million in its fourth quarter. On a per-share basis, the Leiden, Netherlands-based company said it had a loss of 9 cents. The results missed Wall Street expectations.
Kamada (KMDA) Q4 Earnings and Revenues Miss Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -30.80% and -2.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -31.21% and +47.07%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +20.83% and +11.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?